FMP
Evoke Pharma, Inc.
EVOK
NASDAQ
Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray that has completed Phase 3 clinical trials to treat symptoms associated with acute and recurrent diabetic gastroparesis in females. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.
5.07 USD
-0.42 (-8.28%)
We are unable to load the chart at this time.
Mr. Matthew J. D'Onofrio MBA
Healthcare
Drug Manufacturers - Specialty & Generic
NASDAQ
Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray that has completed Phase 3 clinical trials to treat symptoms associated with acute and recurrent diabetic gastroparesis in females. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.
0001403708
US30049G2030
30049G104
420 Stevens Avenue
858 345 1494
US
4
Sep 25, 2013
We are unable to load the chart at this time.
We are unable to load the chart at this time.
0001403708
NASDAQ
Drug Manufacturers -...
Healthcare
30049G104
US30049G2030
US
5.07
0.35
397.79k
7.53M
-
3.54-14.04
-0.15
-
-
-
-
-0.5
-
https://www.evokepharma.com
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
It looks like there's no news available.